ODAC recommends approval for Mylan and Biocon's proposed biosimilar trastuzumab

Mylan and Biocon to now engage with USFDA for final approval

Mylan N.V. and Biocon announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of the companies' proposed biosimilar trastuzumab. The committee voted 16-0 in support of eligible indications of the reference product, Herceptin, which include HER2-positive breast cancer in the metastatic and adjuvant settings.

Mylan and Biocon's proposed biosimilar trastuzumab also is under review by regulatory authorities in Australia, Canada, Europe and several emerging markets.

Powered by Capital Market - Live News